These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696 [TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Tarhini AA; Leng S; Moschos SJ; Yin Y; Sander C; Lin Y; Gooding WE; Kirkwood JM J Immunother; 2012 May; 35(4):359-66. PubMed ID: 22495394 [TBL] [Abstract][Full Text] [Related]
8. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882 [TBL] [Abstract][Full Text] [Related]
9. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986 [TBL] [Abstract][Full Text] [Related]
10. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF. Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM Front Immunol; 2020; 11():1147. PubMed ID: 32582212 [TBL] [Abstract][Full Text] [Related]
12. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients. Atzpodien J; Fluck M; Reitz M Cancer Biother Radiopharm; 2004 Dec; 19(6):758-63. PubMed ID: 15665624 [TBL] [Abstract][Full Text] [Related]
13. Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells. Na IK; Keilholz U; Letsch A; Bauer S; Asemissen AM; Nagorsen D; Thiel E; Scheibenbogen C Cancer Immunol Immunother; 2007 Mar; 56(3):391-6. PubMed ID: 16850346 [TBL] [Abstract][Full Text] [Related]
14. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. Scheibenbogen C; Schmittel A; Keilholz U; Allgäuer T; Hofmann U; Max R; Thiel E; Schadendorf D J Immunother; 2000; 23(2):275-81. PubMed ID: 10746554 [TBL] [Abstract][Full Text] [Related]
15. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Slingluff CL; Petroni GR; Olson WC; Smolkin ME; Ross MI; Haas NB; Grosh WW; Boisvert ME; Kirkwood JM; Chianese-Bullock KA Clin Cancer Res; 2009 Nov; 15(22):7036-44. PubMed ID: 19903780 [TBL] [Abstract][Full Text] [Related]
16. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718 [TBL] [Abstract][Full Text] [Related]
17. Specific central memory T cells in the bone marrow of patients immunized against tyrosinase peptides. Letsch A; Keilholz U; Kern F; Asemissen AM; Thiel E; Scheibenbogen C J Immunother; 2006; 29(2):201-7. PubMed ID: 16531820 [TBL] [Abstract][Full Text] [Related]
18. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Kwak LW; Young HA; Pennington RW; Weeks SD Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293 [TBL] [Abstract][Full Text] [Related]
19. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257 [TBL] [Abstract][Full Text] [Related]
20. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]